查看购物车
  • Traditional Chinese
  • English
  • Japanese
2021-2031 年北美药物警戒和药物安全软体市场报告（范围、细分、动态和竞争分析）
市场调查报告书
商品编码
1819687

2021-2031 年北美药物警戒和药物安全软体市场报告（范围、细分、动态和竞争分析）

North America Pharmacovigilance and Drug Safety Software Market Report 2021-2031 by Scope, Segmentation, Dynamics, and Competitive Analysis
出版日期: | 出版商: The Insight Partners | 英文 210 Pages | 订单完成后即时交付

价格

2023 年北美药物警戒和药物安全软体市场价值约为 1.0003 亿美元，预计到 2031 年将增长至约 1.8272 亿美元，在 2023 年至 2031 年的预测期内年复合成长率(CAGR) 为 7.8%。

药物不良反应发生率不断上升

药物不良反应 (ADR) 的增加是推动北美药物警戒和药物安全软体市场成长的重要因素。慢性病的盛行率不断上升，导致处方药数量增加，进而增加了 ADR 的可能性。鑑于所有药物都可能引起不良反应，因此在开立处方时进行彻底的风险效益分析至关重要。 ADR 对当代医疗保健构成了巨大的挑战，尤其是在治疗方案日益复杂、人口老化以及多种慢性疾病日益流行的背景下。

药物警戒软体在帮助医疗保健提供者和製药公司係统地收集、分析和报告与ADR相关的资料发挥着至关重要的作用。该软体对于应对ADR带来的挑战至关重要，美国食品药物管理局不良事件通报系统（FAERS）的资料就证明了这一点。该系统仅在2022年就报告了超过125万例严重不良反应病例和超过17.5万例死亡病例。

某些药物（例如茶碱与大环内酯类抗生素的相互作用以及维生素K用量增加）与不良反应（ADR）有关。随着报告的ADR数量持续增加，製药公司、医疗保健提供者和监管机构面临越来越大的压力，需要加强药品安全监测和报告流程。药物警戒和药物安全软体简化了不良反应的检测、评估和预防，从而加快了反应速度并提高了风险评估的准确性。因此，ADR发生率的上升是药物警戒和药物安全软体市场成长的关键驱动力。

北美市场概况

北美药物警戒和药品安全软体市场细分为美国、加拿大和墨西哥。北美被认为是最早采用药品安全法规的地区。此外，该地区的製药业数位化进程正在加速。据加拿大健康资讯网 (Canada Health Infoway) 称，加拿大的製药公司越来越多地采用数位医疗服务，预计这将在未来几年推动对药物警戒和药品安全软体的需求。製药业日益增长的数位化预计将增强对有效药品监控的需求，从而增加对药物警戒解决方案的需求。

随着报告的不良事件数量的增加，药物警戒和药物安全专业人员在准确有效地评估这些资料方面面临更大的挑战。先进技术的实施对于减轻这些专业人员的工作量，同时确保对不良事件资料进行精确和系统的分析至关重要。

市场区隔分析

北美药物警戒和药物安全软体市场可以根据各种因素进行分类，包括产品、部署、企业规模、形式、功能、最终用户和国家。

1. 产品：市场分为软体和服务，其中软体部分在 2023 年将占据更大的份额。

2. 部署：市场进一步细分为基于云端的解决方案和内部部署解决方案，其中云端解决方案将在 2023 年占据主导市场份额。

3. 企业规模：市场分为大型企业和中小型企业 (SME)，其中大型企业在 2023 年占据相当大的份额。

4.表格：软体提供标准表格和定製表格，其中标准表格在市场上较为流行。

5. 功能：市场包括讯号和风险管理、问题追踪、案例管理、临床安全管理、品质和合规性以及医疗保健分析等各种功能，其中讯号和风险管理将成为 2023 年最大的细分市场。

6. 最终用户：主要最终用户包括製药和生物技术公司、合约研究组织和业务流程外包公司，其中製药和生物技术公司占据领先市场份额。

7. 国家：市场分为美国、加拿大和墨西哥，美国将在 2023 年占据市场主导地位。

市场关键参与者

北美药物警戒和药物安全软体市场活跃着多家知名公司，包括Veeva Systems Inc.、IQVIA Holdings Inc.、AB Cube SAS、ArisGlobal LLC、甲骨文公司、Max Application、ICON Plc、Cognizant Technology Solutions Corp、埃森哲公司、Syneos Health Inc.、Genpact Ltd.、LabPartory Corpc Technologies、 Holdingspine、Cakak）这些公司在开发创新解决方案以加强该地区药物安全和药物警戒实践方面处于领先地位。

目录

第一章：简介

第二章：执行摘要

  • 关键见解
  • 市场吸引力

第三章：研究方法

  • 二次研究
  • 初步研究
    • 假设表述：
    • 宏观经济因素分析：
    • 显影基数：
    • 数据三角测量：
    • 国家级资料：
  • 假设和局限性

第四章：北美药物警戒与药品安全软体市场格局

  • 概述
    • 软体/服务提供者：
    • 系统整合商：
    • 监理机构：
    • 最终用户：
  • 价值链中的供应商列表

第五章：北美药物警戒与药品安全软体市场－关键市场动态

  • 市场驱动因素
    • 药物不良反应发生率上升
    • 药物警戒全球化
    • 药物开发支出激增
  • 市场限制
    • 安装和维护成本高
  • 市场机会
    • 软体与 AI、ML 和 NLP 的集成
  • 未来趋势
    • 基于云端的药物警戒和药物安全软体：
  • 驱动因素和限制因素的影响：

第六章：北美药物警戒与药品安全软体市场 - 分析

  • 2021-2031年北美药物警戒与药物安全软体市场收入
  • 北美药物警戒与药品安全软体市场预测分析

第七章：北美药物警戒和药品安全软体市场分析 - 按产品

  • 软体
  • 服务

第 8 章：北美药物警戒与药物安全软体市场分析 - 按部署

  • 云
  • 本地

第九章：北美药物警戒与药品安全软体市场分析－依企业规模

  • 大型企业
  • 中小企业

第 10 章：北美药物警戒和药品安全软体市场分析 - 按形式

  • 标准
  • 客製化

第 11 章：北美药物警戒和药品安全软体市场分析 - 按功能

  • 讯号和风险管理
  • 问题跟踪和不良事件跟踪
  • 案件管理
  • 临床安全管理与临床试验安全
  • 品质与合规
  • 医学写作
  • 审计支援和培训合规性
  • 医疗保健分析
  • 其他的

第 12 章：北美药物警戒和药物安全软体市场分析 - 按最终用户

  • 製药和生物技术公司
  • 合约研究组织
  • 业务流程外包（BPO）公司
  • 其他的

第 13 章：北美药物警戒与药品安全软体市场 - 国家分析

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥

第 14 章：竞争格局

  • 关键参与者的热图分析
  • 公司定位与集中度

第十五章：产业格局

  • 概述
  • 市场倡议
  • 伙伴关係与合作

第 16 章：公司简介

  • ArisGlobal LLC
  • Max Application
  • Oracle Corp
  • Veeva Systems Inc
  • IQVIA Holdings Inc
  • ICON Plc
  • Cognizant Technology Solutions Corp
  • Accenture Plc
  • Syneos Health Inc
  • Genpact Ltd.
  • AB Cube S.A.S.
  • Laboratory Corp of America Holdings
  • Parexel International Corp
  • Qinecsa Solutions
  • Clinevo Technologies

第 17 章：附录

Product Code: TIPRE00022774

The North American pharmacovigilance and drug safety software market was valued at approximately $100.03 million in 2023 and is projected to grow to about $182.72 million by 2031, reflecting a compound annual growth rate (CAGR) of 7.8% during the forecast period from 2023 to 2031.

Increasing Incidence of Adverse Drug Reactions

The rise in adverse drug reactions (ADRs) is a significant factor driving the growth of the pharmacovigilance and drug safety software market in North America. The prevalence of chronic diseases is on the rise, leading to an increase in the number of medications prescribed, which in turn raises the potential for ADRs. Given that all medications can cause adverse reactions, conducting a thorough risk-benefit analysis is crucial whenever a drug is prescribed. ADRs pose a considerable challenge in contemporary healthcare, especially with the increasing complexity of treatment regimens, an aging population, and the prevalence of multiple chronic conditions.

Pharmacovigilance software plays a vital role in enabling healthcare providers and pharmaceutical companies to systematically collect, analyze, and report data related to ADRs. This software is essential for addressing the challenges posed by ADRs, as evidenced by the data from the US Food and Drug Administration's Adverse Event Reporting System (FAERS), which reported over 1.25 million severe adverse cases and more than 175,000 deaths in 2022 alone.

The interaction of certain medications, such as theophylline with macrolide antibiotics and increased vitamin K consumption, has been linked to ADRs. As the number of reported ADRs continues to rise, there is increasing pressure on pharmaceutical companies, healthcare providers, and regulatory bodies to enhance drug safety monitoring and reporting processes. Pharmacovigilance and drug safety software streamline the detection, assessment, and prevention of adverse effects, facilitating quicker response times and more accurate risk assessments. Consequently, the growing incidence of ADRs is a key driver of market growth in pharmacovigilance and drug safety software.

Overview of the North American Market

The North American pharmacovigilance and drug safety software market is segmented into the United States, Canada, and Mexico. North America is recognized as an early adopter of regulations concerning pharmaceutical and drug safety. Additionally, the region is witnessing a surge in digitization within the pharmaceutical sector. According to Canada Health Infoway, pharmaceutical companies in Canada are increasingly adopting digital health services, which is expected to drive demand for pharmacovigilance and drug safety software in the coming years. The growing digitization in the pharmaceutical industry is anticipated to enhance the need for effective monitoring of pharmaceutical drugs, thereby increasing the demand for pharmacovigilance solutions.

As the volume of reported adverse events rises, pharmacovigilance and drug safety professionals face greater challenges in accurately and efficiently evaluating this data. The implementation of advanced technologies is crucial to alleviate the workload of these professionals while ensuring precise and systematic analysis of adverse event data.

Market Segmentation Analysis

The North American pharmacovigilance and drug safety software market can be categorized based on various factors, including offering, deployment, enterprise size, form, functionality, end user, and country.

1. Offering: The market is divided into software and services, with the software segment holding a larger share in 2023.

2. Deployment: The market is further segmented into cloud-based and on-premises solutions, with cloud solutions dominating the market share in 2023.

3. Enterprise Size: The market is categorized into large enterprises and small to medium-sized enterprises (SMEs), with large enterprises holding a significant share in 2023.

4. Form: The software is available in standard and customized forms, with the standard form being more prevalent in the market.

5. Functionality: The market includes various functionalities such as signal and risk management, issue tracking, case management, clinical safety management, quality and compliance, and healthcare analytics, with signal and risk management being the largest segment in 2023.

6. End User: The primary end users include pharmaceutical and biotechnology companies, contract research organizations, and business process outsourcing firms, with pharmaceutical and biotechnology companies leading the market share.

7. Country: The market is segmented into the US, Canada, and Mexico, with the US dominating the market in 2023.

Key Players in the Market

Several prominent companies are active in the North American pharmacovigilance and drug safety software market, including Veeva Systems Inc., IQVIA Holdings Inc., AB Cube S.A.S., ArisGlobal LLC, Oracle Corp, Max Application, ICON Plc, Cognizant Technology Solutions Corp, Accenture Plc, Syneos Health Inc., Genpact Ltd., Laboratory Corp of America Holdings, Parexel International Corp, Qinecsa Solutions, and Clinevo Technologies. These companies are at the forefront of developing innovative solutions to enhance drug safety and pharmacovigilance practices in the region.

Table Of Contents

1. Introduction

  • 1.1 Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macroeconomic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country-level data:
  • 3.3 Assumptions and Limitations

4. North America Pharmacovigilance and Drug Safety Software Market Landscape

  • 4.1 Overview
    • 4.1.1 Software/Service Providers:
    • 4.1.2 System Integrators:
    • 4.1.3 Regulatory Bodies:
    • 4.1.4 End-Users:
  • 4.2 List of Vendors in the Value Chain

5. North America Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics

  • 5.1
  • 5.1 Market Drivers
    • 5.1.1 Rise in Incidences of Adverse Drug Reactions
    • 5.1.2 Globalization of Pharmacovigilance
    • 5.1.3 Surge in Drug Development Spending
  • 5.2 Market Restraints
    • 5.2.1 High Installation and Maintenance Costs
  • 5.3 Market Opportunities
    • 5.3.1 Integration of Software with AI, ML, and NLP
  • 5.4 Future Trends
    • 5.4.1 Cloud-Based Pharmacovigilance and Drug Safety Software:
  • 5.5 Impact of Drivers and Restraints:

6. North America Pharmacovigilance and Drug Safety Software Market - Analysis

  • 6.1 North America Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
  • 6.2 North America Pharmacovigilance and Drug Safety Software Market Forecast Analysis

7. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Offering

  • 7.1 Software
    • 7.1.1 Overview
    • 7.1.2 Software: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 7.2 Services
    • 7.2.1 Overview
    • 7.2.2 Services: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

8. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Deployment

  • 8.1 Cloud
    • 8.1.1 Overview
    • 8.1.2 Cloud: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 8.2 On Premises
    • 8.2.1 Overview
    • 8.2.2 On Premises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

9. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Enterprise Size

  • 9.1 Large Enterprises
    • 9.1.1 Overview
    • 9.1.2 Large Enterprises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 9.2 SMEs
    • 9.2.1 Overview
    • 9.2.2 SMEs: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

10. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Form

  • 10.1 Standard
    • 10.1.1 Overview
    • 10.1.2 Standard: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 10.2 Customized
    • 10.2.1 Overview
    • 10.2.2 Customized: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

11. North America Pharmacovigilance and Drug Safety Software Market Analysis - by Functionality

  • 11.1 Signal and Risk Management
    • 11.1.1 Overview
    • 11.1.2 Signal and Risk Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.2 Issue Tracking and Adverse Event Tracking
    • 11.2.1 Overview
    • 11.2.2 Issue Tracking and Adverse Event Tracking: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.3 Case Management
    • 11.3.1 Overview
    • 11.3.2 Case Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.4 Clinical Safety Management and Clinical Trial Safety
    • 11.4.1 Overview
    • 11.4.2 Clinical Safety Management and Clinical Trial Safety: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.5 Quality and Compliance
    • 11.5.1 Overview
    • 11.5.2 Quality and Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.6 Medical Writing
    • 11.6.1 Overview
    • 11.6.2 Medical Writing: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.7 Audit Support and Training Compliance
    • 11.7.1 Overview
    • 11.7.2 Audit Support and Training Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.8 Healthcare Analytics
    • 11.8.1 Overview
    • 11.8.2 Healthcare Analytics: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 11.9 Others
    • 11.9.1 Overview
    • 11.9.2 Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

12. North America Pharmacovigilance and Drug Safety Software Market Analysis - by End User

  • 12.1 Pharmaceutical and Biotechnology Companies
    • 12.1.1 Overview
    • 12.1.2 Pharmaceutical and Biotechnology Companies: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.2 Contract Research Organizations
    • 12.2.1 Overview
    • 12.2.2 Contract Research Organizations: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.3 Business Process Outsourcing (BPO) Firms
    • 12.3.1 Overview
    • 12.3.2 Business Process Outsourcing (BPO) Firms: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • 12.4 Others
    • 12.4.1 Overview
    • 12.4.2 Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)

13. North America Pharmacovigilance and Drug Safety Software Market - Country Analysis

  • 13.1 North America
    • 13.1.1 North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
      • 13.1.1.1 North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast Analysis - by Country
      • 13.1.1.2 United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.2.1 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.2.1 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.2.2 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.2.3 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.2.4 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.2.5 United States: North America Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.3 Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.3.1 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.3.2 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.3.3 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.3.4 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.3.5 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.3.6 Canada: North America Pharmacovigilance and Drug Safety Software Market Share - by End User
      • 13.1.1.4 Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
        • 13.1.1.4.1 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Offering
        • 13.1.1.4.2 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Deployment
        • 13.1.1.4.3 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Enterprise Size
        • 13.1.1.4.4 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Form
        • 13.1.1.4.5 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by Functionality
        • 13.1.1.4.6 Mexico: North America Pharmacovigilance and Drug Safety Software Market Share - by End User

14. Competitive Landscape

  • 14.1 Heat Map Analysis by Key Players
  • 14.2 Company Positioning and Concentration

15. Industry Landscape

  • 15.1 Overview
  • 15.2 Market Initiative
  • 15.3 Partnerships and Collaborations

16. Company Profiles

  • 16.1 ArisGlobal LLC
    • 16.1.1 Key Facts
    • 16.1.2 Business Description
    • 16.1.3 Products and Services
    • 16.1.4 Financial Overview
    • 16.1.5 SWOT Analysis
    • 16.1.6 Key Developments
  • 16.2 Max Application
    • 16.2.1 Key Facts
    • 16.2.2 Business Description
    • 16.2.3 Products and Services
    • 16.2.4 Financial Overview
    • 16.2.5 SWOT Analysis
    • 16.2.6 Key Developments
  • 16.3 Oracle Corp
    • 16.3.1 Key Facts
    • 16.3.1 Business Description
    • 16.3.2 Products and Services
    • 16.3.3 Financial Overview
    • 16.3.4 SWOT Analysis
    • 16.3.5 Key Developments
  • 16.4 Veeva Systems Inc
    • 16.4.1 Key Facts
    • 16.4.2 Business Description
    • 16.4.3 Products and Services
    • 16.4.4 Financial Overview
    • 16.4.5 SWOT Analysis
    • 16.4.6 Key Developments
  • 16.5 IQVIA Holdings Inc
    • 16.5.1 Key Facts
    • 16.5.2 Business Description
    • 16.5.3 Products and Services
    • 16.5.4 Financial Overview
    • 16.5.5 SWOT Analysis
    • 16.5.6 Key Developments
  • 16.6 ICON Plc
    • 16.6.1 Key Facts
    • 16.6.2 Business Description
    • 16.6.3 Products and Services
    • 16.6.4 Financial Overview
    • 16.6.5 SWOT Analysis
    • 16.6.6 Key Developments
  • 16.7 Cognizant Technology Solutions Corp
    • 16.7.1 Key Facts
    • 16.7.2 Business Description
    • 16.7.3 Products and Services
    • 16.7.4 Financial Overview
    • 16.7.5 SWOT Analysis
    • 16.7.6 Key Developments
  • 16.8 Accenture Plc
    • 16.8.1 Key Facts
    • 16.8.2 Business Description
    • 16.8.3 Products and Services
    • 16.8.4 Financial Overview
    • 16.8.5 SWOT Analysis
    • 16.8.6 Key Developments
  • 16.9 Syneos Health Inc
    • 16.9.1 Key Facts
    • 16.9.2 Business Description
    • 16.9.3 Products and Services
    • 16.9.4 Financial Overview
    • 16.9.5 SWOT Analysis
    • 16.9.6 Key Developments
  • 16.10 Genpact Ltd.
    • 16.10.1 Key Facts
    • 16.10.2 Business Description
    • 16.10.3 Products and Services
    • 16.10.4 Financial Overview
    • 16.10.5 SWOT Analysis
    • 16.10.6 Key Developments
  • 16.11 AB Cube S.A.S.
    • 16.11.1 Key Facts
    • 16.11.2 Business Description
    • 16.11.3 Products and Services
    • 16.11.4 Financial Overview
    • 16.11.5 SWOT Analysis
    • 16.11.6 Key Developments
  • 16.12 Laboratory Corp of America Holdings
    • 16.12.1 Key Facts
    • 16.12.2 Business Description
    • 16.12.3 Products and Services
    • 16.12.4 Financial Overview
    • 16.12.5 SWOT Analysis
    • 16.12.6 Key Developments
  • 16.13 Parexel International Corp
    • 16.13.1 Key Facts
    • 16.13.2 Business Description
    • 16.13.3 Products and Services
    • 16.13.4 Financial Overview
    • 16.13.5 SWOT Analysis
    • 16.13.6 Key Developments
  • 16.14 Qinecsa Solutions
    • 16.14.1 Key Facts
    • 16.14.2 Business Description
    • 16.14.3 Products and Services
    • 16.14.4 Financial Overview
    • 16.14.5 SWOT Analysis
    • 16.14.6 Key Developments
  • 16.15 Clinevo Technologies
    • 16.15.1 Key Facts
    • 16.15.2 Business Description
    • 16.15.3 Products and Services
    • 16.15.4 Financial Overview
    • 16.15.5 SWOT Analysis
    • 16.15.6 Key Developments

17. Appendix

  • 17.1 About Us
  • 17.2 List of Abbreviations

List Of Tables

  • Table 1. North America Pharmacovigilance and Drug Safety Software Market Segmentation
  • Table 2. List of Vendors
  • Table 3. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Table 4. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Offering
  • Table 5. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Deployment
  • Table 6. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Enterprise Size
  • Table 7. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Form
  • Table 8. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Functionality
  • Table 9. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by End User
  • Table 10. North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand) - by Country
  • Table 11. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 12. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 13. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 14. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 15. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 16. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 17. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 18. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 19. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 20. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 21. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 22. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 23. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Offering
  • Table 24. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Deployment
  • Table 25. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Enterprise Size
  • Table 26. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Form
  • Table 27. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by Functionality
  • Table 28. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021 - 2031 (US$ Thousand) - by End User
  • Table 29. List of Abbreviations

List Of Figures

  • Figure 1. North America Pharmacovigilance and Drug Safety Software Market Segmentation - Country
  • Figure 2. Ecosystem Analysis
  • Figure 3. North America Pharmacovigilance and Drug Safety Software Market - Key Market Dynamics
  • Figure 4. Impact Analysis of Drivers and Restraints
  • Figure 5. North America Pharmacovigilance and Drug Safety Software Market Revenue (US$ Thousand), 2021-2031
  • Figure 6. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by Offering (2023 and 2031)
  • Figure 7. Software: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 8. Services: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 9. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by Deployment (2023 and 2031)
  • Figure 10. Cloud: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 11. On Premises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 12. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by Enterprise Size (2023 and 2031)
  • Figure 13. Large Enterprises: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 14. SMEs: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 15. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by Form (2023 and 2031)
  • Figure 16. Standard: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 17. Customized: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 18. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by Functionality (2023 and 2031)
  • Figure 19. Signal and Risk Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 20. Issue Tracking and Adverse Event Tracking: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 21. Case Management: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 22. Clinical Safety Management and Clinical Trial Safety: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 23. Quality and Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 24. Medical Writing: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 25. Audit Support and Training Compliance: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 26. Healthcare Analytics: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 27. Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 28. North America Pharmacovigilance and Drug Safety Software Market Share (%) - by End User (2023 and 2031)
  • Figure 29. Pharmaceutical and Biotechnology Companies: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 30. Contract Research Organizations: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 31. Business Process Outsourcing (BPO) Firms: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 32. Others: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021-2031 (US$ Thousand)
  • Figure 33. North America Pharmacovigilance and Drug Safety Software Market Breakdown, by Key Countries, 2023 and 2031 (%)
  • Figure 34. United States: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 35. Canada: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 36. Mexico: North America Pharmacovigilance and Drug Safety Software Market - Revenue and Forecast, 2021- 2031 (US$ Thousand)
  • Figure 37. Heat Map Analysis by Key Players
  • Figure 38. Company Positioning and Concentration